Clinical trial · Observational
A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan
Clinical Correlation of Alpha-Fetoprotein in Hepatocellular Carcinoma: a Cross-Sectional Study from Southeast Asia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC). The goal is to determine whether AFP levels vary based on the size of the liver tumor or other health conditions like hepatitis B, hepatitis C, and obesity. By analyzing data from 94 patients, the study seeks to identify factors that influence AFP levels, which may help in understanding liver cancer progression and improving diagnosis and treatment approaches.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Group 1: HCC Patients with Elevated AFP Levels Description: This group includes patients diagnosed
Primary outcomes (1)
- measure
- Mean Alpha-Fetoprotein (AFP) Levels in HCC Patients
- timeFrame
- Baseline measurement at time of diagnosis.
Secondary outcomes (1)
- measure
- Correlation Between AFP Levels and Tumor Size
- timeFrame
- At baseline (upon diagnosis).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 27 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Aged between 27 to 80 years. * Diagnosed with hepatocellular carcinoma (HCC) within the last three months. * Diagnosis confirmed by relevant investigations (e.g., imaging, liver biopsy). * Able to provide informed consent. Exclusion Criteria: * Elevated alpha-fetoprotein levels due to tumors other than HCC. * Presence of secondary liver metastases from other primary sites. * Any significant comorbid conditions that could interfere with study assessments. * Pregnancy or breastfeeding.
References
Publications (0)
Data not yet available